The TGA has issued a safety alert regarding the possibility of eltrombopag (Revolade) interfering with laboratory tests such as total bilirubin and creatinine. The thrombopoietin receptor (TPO-R) agonist can be hepatotoxic and the manufacturer advises monitoring of ALT, AST and bilirubin. Creatinine monitoring is also advised in patients with renal disease. However the highly coloured ...
Eltrombopag can interfere with lab tests
By Mardi Chapman
13 Nov 2018